Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of a New Ultra Low Molecular Weight Heparin (RO-14) Administered Subcutaneously Increasing Single-doses to Healthy Male Volunteers

Phase 1 Completed 12 enrolled Rovi Pharmaceuticals Laboratories

RandomizedCrossoverOpen-labelTreatment

Summary

Clinical trial to evaluate the tolerability and pharmacokinetics of a new ultra low molecular weight heparin (RO-14) administered subcutaneously increasing single-doses to healthy male volunteers

Timeline

Start: 2007-12
Primary completion: 2007-12
Completion: 2008-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RO-14	Other / unclassified	—	Subcutaneous

Indications

No indication recorded.